Montes de Oca Maria, Laucho-Contreras Maria Eugenia
Hospital Universitario de Caracas, Facultad de Medicina, Los Chaguaramos, Universidad Central de Venezuela, 1053 Caracas, Venezuela.
Servicio de Neumonología, Hospital Universitario de Caracas, Facultad de Medicina, Universidad Central de Venezuela, 1053 Caracas, Venezuela.
Med Sci (Basel). 2018 Jun 14;6(2):50. doi: 10.3390/medsci6020050.
Acute exacerbations in chronic obstructive pulmonary disease (AECOPD) are associated with increased mortality, rate of hospitalization, use of healthcare resources, and have a negative impact on disease progression, quality of life and lung function of patients with chronic obstructive pulmonary disease (COPD). There is an imperative need to homogenize the definition of AECOPD because the incidence of exacerbations has a significant influence or implication on treatment decision making, particularly in pharmacotherapy and could impact the outcome or change the statistical significance of a therapeutic intervention in clinical trials. In this review, using PubMed searches, we have analyzed the weaknesses and strengths of the different used AECOPD definitions (symptom-based, healthcare-based definition or the combinations of both), as well as the findings of the studies that have assessed the relationship of different biomarkers with the diagnosis, etiology and differential diagnosis of AECOPD and the progress towards the development of a more precise definition of COPD exacerbation. Finally, we have proposed a simple definition of AECOPD, which must be validated in future clinical trials to define its accuracy and usefulness in daily practice.
慢性阻塞性肺疾病急性加重(AECOPD)与死亡率增加、住院率升高、医疗资源使用增多相关,并且对慢性阻塞性肺疾病(COPD)患者的疾病进展、生活质量和肺功能产生负面影响。迫切需要统一AECOPD的定义,因为加重的发生率对治疗决策有重大影响,尤其是在药物治疗方面,并且可能影响临床试验中治疗干预的结果或改变其统计学意义。在本综述中,我们通过PubMed检索,分析了不同的AECOPD定义(基于症状的定义、基于医疗保健的定义或两者的组合)的优缺点,以及评估不同生物标志物与AECOPD的诊断、病因和鉴别诊断之间关系的研究结果,以及在制定更精确的COPD加重定义方面取得的进展。最后,我们提出了一个简单的AECOPD定义,该定义必须在未来的临床试验中进行验证,以确定其在日常实践中的准确性和实用性。